Effects of Angiotensin Receptor Antagonist on Prohibiting Cardiovascular Events on Hemodialysis Patients

Saitama Medical University

Status: Completed

Conditions: Cardiovascular Disease

Treatments: Drug: candesartan or valsartan or losartan

Study type: Interventional

Funder types: Other

Identifiers

NCT00530595

S-01

Details and patient eligibility

About

Cardiovascular disease is a leading cause of mortality in patients on hemodialysis therapy (HD), accounting for 30 to 50% of all death. Although angiotensin receptor blockers (ARBs) are effective for patients with diabetes and chronic kidney disease in reducing or preventing cardiovascular diseases, there has been no decisive study that demonstrated treatment with ARBs is effective in patients on HD.

Sex: All

Ages: 30 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• 30 to 80 years of age
• Receiving hemodialysis at least 12 months and less than 5 years
• Pre-dialysis systolic blood pressure was more than 160 mmHg, or more than 150 mmHg if the patients received antihypertensive agents.

Exclusion criteria

• Use of angiotensin receptor blocker or angiotensin converting enzyme inhibitor

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)